Back to Search Start Over

Nuclear factor kappa B expression in non-small cell lung cancer.

Authors :
Zhang, Leilei
Ludden, Claudia M.
Cullen, Alexander J.
Tew, Kenneth D.
Branco de Barros, André Luís
Townsend, Danyelle M.
Source :
Biomedicine & Pharmacotherapy. Nov2023, Vol. 167, pN.PAG-N.PAG. 1p.
Publication Year :
2023

Abstract

In this mini-review, we discuss the role of NF-κB, a proinflammatory transcription factor, in the expression of genes involved in inflammation, proliferation, and apoptosis pathways, and link it with prognosis of various human cancers, particularly non-small cell lung cancer (NSCLC). We and others have shown that NF-κB activity can be impacted by post-translational S-glutathionylation through reversible formation of a mixed disulfide bond between its cysteine residues and glutathione (GSH). Clinical data analysis showed that high expression of NF-κB correlated with shorter overall survival (OS) in NSCLC patients, suggesting a tumor promotion function for NF-κB. Moreover, NF-κB expression was associated with tumor stage, lymph node metastasis, and 5-year OS in these patients. NF-κB was over-expressed in the cytoplasm of tumor tissue compared to adjacent normal tissues. S-glutathionylation of NF-κB caused negative regulation by interfering with DNA binding activities of NF-κB subunits. In response to oxidants, S-glutathionylation of NF-κB also correlated with enhanced lung inflammation. Thus, S-glutathionylation is an important contributor to NF-κB regulation and clinical results highlight the importance of NF-κB in NSCLC, where NF-κB levels are associated with unfavorable prognosis. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
07533322
Volume :
167
Database :
Academic Search Index
Journal :
Biomedicine & Pharmacotherapy
Publication Type :
Academic Journal
Accession number :
172976447
Full Text :
https://doi.org/10.1016/j.biopha.2023.115459